COPENHAGEN: Zealand Pharma (Zealand), reports royalty revenue from Sanofi’s global sales of lixisenatide of DKK 6.1 million / € 0.8 million for the period from 1 July to 30 September 2016. For the first nine months of 2016, Zealand’s royalty revenue amounted to DKK 19.0 million / € 2.6 million.
Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment of patients with type 2 diabetes and was invented by Zealand, with global development and commercialization rights licensed to Sanofi. Lixisenatide is marketed under the brand name Lyxumia® in over 45 countries and was approved in the U.S. under the brand name AdlyxinTM in July 2016.
Sanofi has also developed iGlarLixi, a fixed-ratio combination of lixisenatide and insulin glargine 100 units/mL (Lantus®), which is under regulatory review in both the U.S. and Europe. A regulatory decision is expected in November 2016 in the U.S. and in Q1 2017 in Europe.
